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Abstract	
Introduction:	Precision	medicine	describes	a	future	state	where	drug	treatment	is	selected	based	on	a	
patient’s	disease	and	genetics.	Precision	dosing	is	a	key	component	of	precision	medicine,	in	which	
medications	are	adjusted	to	each	individual	patient’s	relevant	characteristics.	The	electronic	medical	
record	(EMR)	has	enabled	the	development	of	precision	dosing	tools	that	can	provide	prescribers	with	
instantaneous	recommendations	for	dose	adjustments	based	on	patient	characteristics	recorded	in	the	
EMR.	Although	these	dosing	tools	exist,	data	evaluating	the	prevalence	of	these	tools	in	the	United	
States	(U.S.)	are	lacking.	The	purpose	of	this	study	was	to	assess	the	availability	and	capability	of	
electronic	dosing	tools	across	U.S.	hospitals.			
Methods:	We	conducted	a	cross-sectional,	observational	study	using	a	self-report	questionnaire	among	
U.S.	pharmacists	to	evaluate	the	prevalence	of	and	attitudes	toward	dosing	tools.	The	survey	was	
developed	using	Qualtrics	(Qualtrics,	Provo,	UT)	and	sent	to	the	chairs	of	relevant	ACCP	PRN	Networks	
for	dissemination	to	their	members.	Data	were	analyzed	based	on	frequency	of	response	to	each	survey	
question.		
Results:	One-hundred	fourteen	pharmacists	completed	the	survey,	of	which	30%	reported	having	dosing	
tools	integrated	into	their	EMR.	Among	those	respondents	who	do	not	have	dosing	tools	available,	59%	
reported	that	they	have	strong	interest	in	obtaining	these	tools.	
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Conclusions:	Based	on	the	results	of	this	survey,	few	U.S.	hospitals	have	drug	dosing	tools	available,	
demonstrating	a	need	for	the	development	of	such	tools	that	are	affordable,	accurate,	and	accessible	
for	integration	into	the	EMR.	
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Introduction:	
Precision	medicine	describes	a	future	state	where	treatment	is	customized	to	a	patient’s	disease,	
genetics,	environment,	and	lifestyle.	A	major	component	of	precision	medicine	is	precision	dosing,	in	
which	the	drug	dose	is	adjusted	to	each	individual	patient’s	relevant	characteristics	(e.g.,	weight,	age,	
renal	function,	liver	function,	drug	interactions,	and	genetics)	to	increase	the	likelihood	for	patients	to	
achieve	drug	efficacy	with	minimal	toxicity.1,2	The	application	of	precision	dosing	has	significantly	
improved	with	the	development	of	large-scale	biologic	databases	that	contain	accessible	information	
regarding	proteomics,	metabolomics,	and	genomics.3	In	addition,	the	electronic	medical	record	(EMR)	
has	enabled	the	development	of	more	sophisticated	precision	dosing	tools	that	can	provide	prescribers	
with	real-time	recommendations	for	dose	adjustments	based	on	patient	characteristics	recorded	in	the	
EMR.	The	current	EMR	environment	has	the	ability	to	access	each	patient’s	pertinent	information	such	
as		age,	size,	and	laboratory	results,		to	enable	more	precisely	calculated	drug	dosing.	Additionally,	
clinical	support	software	tools	aligned	with	the	EMR	offer	the	ability	to	instantaneously	calculate	drug	
dosing	based	on	prior	knowledge	such	as	doses	or	drug	plasma	concentrations	associated	with	efficacy	
and	toxicity.	While	many	EMR	platforms	have	the	ability	to	integrate	these	tools,	we	are	not	aware	of	
the	electronic	dosing	tool	prevalence	in	the	U.S.	Therefore,	we	developed	a	survey	to	assess	the	
availability	and	capability	of	electronic	dosing	tools	across	U.S	hospitals.		
Methods:	
A	cross-sectional,	observational	study	using	a	self-report	questionnaire	was	designed	to	assess	the	
availability	of	dosing	tools	integrated	into	EMRs	across	the	U.S.	The	survey	was	created	using	Qualtrics	
(Qualtrics,	Provo,	UT)	and	provided	to	chairs	of	the	following	American	College	of	Clinical	Pharmacy	
(ACCP)	Practice	and	Research	Networks	(PRNs)	for	dissemination	to	their	members:	Clinical	
Administration,	Drug	Information,	Cardiology,	Hematology/Oncology,	HIV,	and	Pharmacokinetics,	
Pharmacodynamics,	and	Pharmacogenomics.	The	survey	consisted	of	12	questions	assessing	electronic	
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dosing	tool	availability	at	the	respective	practice	site	of	each	respondent	and	was	expected	to	take	
approximately	10	minutes	to	complete.	Information	was	anonymously	recorded	between	February	15,	
2017	and	April	31,	2017.	The	survey	questions	requested	descriptive	information	about	the	practice	site,	
availability	of	dosing	tools,	capability	of	available	dosing	tools,	attitudes	toward	EMR-integrated	dosing	
tools,	and	barriers	to	integrating	dosing	tools	into	the	EMR.	The	primary	endpoint	assessed	the	
prevalence	of	dosing	tool	availability	in	and	incorporation	the	EMR	across	the	U.S.	In	order	to	be	
classified	as	having	dosing	tool	availability,	respondents	must	have	reported	access	to	marketed	dosing	
platforms	or	locally-developed	protocols	integrated	into	the	EMR	that	allow	for	real-time	dosing	
recommendations	as	the	prescription	is	written	by	the	provider.	Respondents	were	excluded	if	they	did	
not	answer	the	primary	question	regarding	the	availability	of	precision	dosing	tools	at	their	practice	site.	
For	most	parameters,	respondents	were	able	to	select	multiple	responses	that	applied.	Data	were	
analyzed	based	on	frequency	of	response	to	each	survey	question.		
	
Results:	
	 Two-hundred	fifteen	pharmacists	started	the	survey	(Figure	1).	One-hundred	one	responses	
were	excluded,	since	these	respondents	did	not	complete	the	primary	question	of	interest,	which	asked	
a	yes	or	no	question	to	determine	whether	or	not	their	site	had	precision	dosing	tools	integrated	into	
their	EMR.		Among	the	114	remaining	evaluable	respondents,	the	majority	were	clinical	inpatient	
pharmacists	from	academic	medical	centers	or	community	hospitals	with	fewer	than	500	beds	(Table	1).		
Of	these	respondents,	only	30%	have	precision	dosing	software	integrated	in	their	EMR.	Among	those	
sites	with	EMR-integrated	dosing	tools,	24%	use	only	commercially	available	tools,	59%	use	only	tools	
locally	developed	by	their	health	system	or	hospital,	and	18%	use	a	combination	of	commercially	
available	and	locally-developed	tools	(Table	2).	Eight	different	commercially	available	platforms	were	
reported.	VigiLanz	Healthcare	Analytics	was	the	most	commonly	reported,	used	by	three	respondents.	
The	following	platforms	were	each	reported	by	one	respondent:	iKnowMedSM	Generation	2,	Kinetidex®,	
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MedMined®,	OneOme	RightMed,	Sentri7®	-	Pharmacy	OneSource,	TheraDoc®,	and	Zynx	HealthTM.	One	
respondent	reported	that	his	site	is	currently	under	contract	with	a	commercially	available	software,	but	
could	not	provide	the	software	vendor	name.	Another	respondent	did	not	specify	the	name	of	the	
marketed	software	available,	but	indicated	that	the	current	software	alerts	the	prescriber	in	real-time	if	
an	alternative	dose	should	be	recommended.	The	number	of	medications	for	which	the	dosing	tools	are	
utilized	varied	greatly	among	respondents.	Dosing	tool	availability	was	most	commonly	reported	for	use	
with	antimicrobial,	immune-modulating,	and	oncolytic	agents.	Additionally,	a	number	of	respondents	
reported	use	of	dosing	tools	with	phenytoin,	warfarin,	digoxin,	and	clopidogrel.			
	 Of	those	respondents	who	have	dosing	tools	available	and	completed	the	opinion	questions,	
79%	are	satisfied	by	the	tools	available	at	their	institution,	while	17%	are	dissatisfied.	Satisfaction	with	
the	dosing	tools	is	greater	among	those	who	have	commercially	available	tools	versus	those	who	have	
locally-developed	tools	(100%	versus	76%).	There	was	a	notable	difference	in	reported	reliability	
between	those	respondents	with	commercially	available	tools	and	those	respondents	with	locally-
derived	tools	(100%	versus	88%).	These	data	suggest	that	users	feel	dosing	tools	are	more	reliable	when	
they	are	commercially	developed	than	when	they	are	locally	developed.			
Among	those	respondents	without	dosing	tools	available,	59%	responded	that	they	are	
interested	in	obtaining	these	tools	(Table	3).	The	most	commonly	reported	barriers	to	integrating	dosing	
tools	into	the	EMR	include	cost,	disagreement	among	providers	regarding	the	clinical	utility	of	dosing	
tools,	and	lack	of	adequate	EMR	capability.	Other	respondents	reported	that	their	sites	lack	the	
necessary	information	technology	support	to	properly	integrate	the	dosing	tools	into	their	current	EMR	
platforms.	Although	a	number	of	barriers	were	reported,	there	was	not	a	predominant	barrier	to	
integrating	dosing	tools	into	the	EMR.		
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Discussion:	
As	demonstrated	by	both	those	who	have	dosing	tools	integrated	into	the	EMR	and	those	who	
do	not	have	these	applications,	there	is	a	need	for	more	accurate	and	reliable	commercially	available	
dosing	tools	that	can	be	easily	integrated	into	the	EMR.	It	will	be	useful	for	dosing	tool	customers	to	
participate	in	recommending	their	ideal	drug	dosing	tool	characteristics.	For	instance,	drug	dosing	tools	
ought	to	provide	evidence	the	tool	delivers	acceptable	prediction	accuracy	for	the	patient	population	
diversity	in	which	it	is	intended	to	be	used.	The	dosing	tool	user	should	find	the	tool	to	be	both	intuitive	
and	easy	to	use	without	making	mistakes.	Patient	information	needed	to	dose	the	drug	should	be	
automatically	available	from	the	EMR	without	the	need	for	user	input.	Dosing	tools	should	provide	drug	
dosing	suggestions	to	adjust	the	dose,	dosing	interval	or	both	along	with	how	and	when	to	provide	
additional	feedback	information	if	needed.	Depth	of	documentation	should	provide	the	user	with	
information	and	references	if	needed.	Competition	between	dosing	tool	vendors	will	be	worthwhile	to	
meet	these	needs.	
	 Although	this	survey	provides	a	valuable	baseline	assessment	for	dosing	tool	availability	among	
U.S.	hospital	pharmacists,	there	are	a	number	of	limitations	that	should	be	noted.	The	sample	size	is	
relatively	small.	In	addition,	respondents	were	not	required	to	answer	all	questions,	consequently	many	
respondents	did	not	complete	the	opinion	questions,	so	characterization	of	their	attitudes	toward	the	
dosing	tools	used	at	their	sites	is	unavailable.	Further,	the	results	of	the	study	may	be	skewed,	such	that	
an	even	smaller	portion	of	U.S.	hospitals	may	have	dosing	tools	available	than	we	reported,	as	the	
survey	was	sent	only	to	ACCP	members	who	may	represent	clinically	focused	pharmacists	potentially	at	
institutions	more	likely	to	have	dosing	tools.		
Drug	dosing	tools	will	likely	evolve	in	several	ways	beyond	adjusting	the	dose	based	on	a	
perceived	therapeutic	drug	concentration	range.	By	interfacing	with	the	individual	patient’s	relevant	
dosing	information,	the	tool	should	detect	new	opportunities	to	improve	therapeutics	by	notifiying	the	
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prescriber	rather	than	depending	solely	on	the	prescriber’s	knowledge	or	time.	Dosing	tools	need	not	be	
restricted	to	indexing	dosing	to	an	established	‘therapeutic	drug	concentration	range.’	Rather	dosing	
could	also	be	indexed	back	to	the	pivotal	efficacy-safety	clinical	trials	upon	which	FDA	has	approved	the	
drug.	Finally,	dosing	recommendations	can	be	provided	either	with	or	without	the	local	ability	to	
provide	laboratory	biomarker	feedback	information	(e.g.,	drug	concentration,	dynamic	markers).		
										The	evolution	and	access	to	high	quality	dosing	tools	should	improve	patient’s	therapeutic	
experience	in	part	by	elevating	the	practice	of	pharmacy	and	medicine.	High	quality	dosing	tools	should	
make	prescribers	more	informed	resulting	in	higher	quality	practice.	Clinical	pharmacy	is	well	positioned	
to	embrace	drug	dosing	tool	development	because	these	tools	are	central	to	high	quality	practice.		
	 In	the	future,	this	survey	should	be	revised	and	routinely	conducted,	in	order	to	continually	
assess	the	prevalence,	quality	and	acceptability	of	drug	dosing	tools,	so	these	tools	can	be	continuously	
improved	to	meet	user-prescriber	needs.	Future	surveys	should	attempt	to	characterize	the	strengths	
and	limitations	of	the	commercially	available	dosing	tools.	Respondents	should	have	the	opportunity	to	
describe	what	they	like	or	do	not	like	about	the	available	tools,	so	that	developers	can	continue	to	
improve	their	available	platforms.	We	recommend	modifying	this	survey	to	characterize	the	number	of	
tools	that	are	integrated	into	the	EMR.	It	would	be	interesting	to	know	the	extent	that	each	dosing	tool	
has	been	prospectively	tested	for	accuracy	and	precision	and	how	frequently	tools	are	improved	or	
updated.	We	suggest	ACCP	disseminate	this	survey,	as	the	results	are	central	to	its	mission.		
Additionally,	with	the	support	of	a	larger	organization,	a	greater	number	of	responses	can	be	captured.		
Finally,	the	survey	should	also	be	distributed	to	physicians,	nurse	practitioners,	physician	assistants,	and	
other	advanced	practitioners	with	prescriptive	authority.		
	
Conclusions:	
This	survey	is	the	only	known	survey	that	has	assessed	the	availability	of	precision	dosing	software	
in	U.S.	hospitals.	Dosing	tools	are	needed	to	ensure	providers	can	prescribe	safe	and	effective	
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medications	in	an	accurate	and	reliable	manner.	Currently,	there	are	many	hospitals	throughout	the	U.S.	
that	do	not	have	dosing	tools	available,	demonstrating	a	need	for	such	tools	to	be	affordable,	accessible	
and	accurate	for	integration	into	the	EMR.	Additionally,	among	those	who	have	dosing	tools,	there	is	
moderate	satisfaction	with	the	available	tools,	indicating	there	is	a	demand	for	more	accurate	and	
reliable	dosing	tools.		
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Tables	
Table	1.	Baseline	Characteristics	of	Respondents	
	 	
Total	
(n=114)	
Dosing	Tools	
Available	
(n=34)	
Dosing	Tools	Not	
Available	
(n=80)	
	 Percent	of	Respondents	
Current	position	in	pharmacy*	 	 	 	
	 Staff	
Inpatient	Clinical	
Ambulatory	Care	
Administrative	
Other	
5	(4%)	
84	(74%)	
23	(20%)	
7	(6%)	
9	(8%)	
2	(6%)	
26	(76%)	
8	(24%)	
3	(9%)	
3	(9%)	
3	(4%)	
58	(73%)	
15	(19%)	
4	(5%)	
6	(8%)	
Practice	Site	 	 	 	
	 Academic	Medical	Center	
Private	Medical	Center	
Community	Hospital	
VA	or	Gov.	Medical	Center	
Other	
49	(43%)	
7	(6%)	
46	(40%)	
6	(5%)	
6	(5%)	
14	(41%)	
2	(6%)	
15	(44%)	
1	(3%)	
2	(6%)	
35	(44%)	
5	(6%)	
31	(39%)	
5	(6%)	
4	(5%)	
Size	of	Facility	(no.	of	beds)	 	 	 	
	 0	–	499		
500	–	999	
≥	1000	
60	(53%)	
44	(39%)	
10	(8%)	
16	(47%)	
13	(38%)	
5	(15%)	
44	(55%)	
31	(39%)	
5	(6%)	
*Percent	of	respondents	not	expected	to	add	to	100	because	respondents	were	permitted	to	select	
more	than	one	option	per	question	
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Table	2.	Survey	Respondents	Using	Precision	Dosing	Tools	(n	=	34)	
	 Percent	of	
Respondents	
Types	of	Precision	Dosing	Applications*	
Commercially	available	software	
Hospital	or	locally-derived	protocols	
Links	to	precision	dosing	websites	
	
12	(35%)	
26	(76%)	
8	(24%)	
Professions	Utilizing	Dosing	Tools*	
Pharmacists	
Physicians	
Advanced	Practice	Practitioners	
Not	specified	
	
31	(91%)	
21	(62%)	
17	(50%)	
3	(9%)	
Dosing	Tool	Capability*	
Automatic	
Built-in	Alert	
Link	to	External	Tool/Website	
	
18	(53%)	
13	(38%)	
3	(9%)	
Number	of	Medications	for	which	Dosing	Tools	are	Utilized	
None	Reported	
1	to	5	
6	to	10	
>10	
	
9	(26%)	
9	(26%)	
7	(21%)	
9	(26%)	
*Percent	of	respondents	not	expected	to	add	to	100	because	respondents	were	permitted	to	select	
more	than	one	option	per	question	
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Table	3.	Opinions	of	Survey	Respondents	without	Dosing	Tools	Available	(n=22)	
	 	 Percent	of	
Respondents*	
Barriers	to	Integrate	Dosing	Tools	into	the	EMR		 	
	 Current	EMR	unable	to	support	applications	
Available	clinical	decision	support	insufficient	for	practice	site	needs	
Providers	not	interested		
Provider	disagreement	regarding	clinical	utility	of	dosing	tools	
Cost	
Unknown	
Other	
23%	
14%	
14%	
9%	
27%	
36%	
14%	
Importance	of	EMR-Integrated	Dosing	Tools	 	
	 Moderately	to	Extremely			
Slightly	Important	
Not	at	all	Important	
59%	
36%	
5%	
*Percent	of	respondents	not	expected	to	add	to	100	because	respondents	were	permitted	to	select	
more	than	one	option	per	question	
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Figure	
Figure	1.	Consort	diagram	of	respondents	
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